Poster

A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate Camidanlumab Tesirine (Cami) as Monotherapy in Patients with Advanced Solid Tumors

Email this document.

Enter your email address below to send this document.

PLACEHOLDER START

[ninja_form id=1]

Important Notice

I am a Healthcare Professional registered to practice in the U.S.
I am a U.S. Patient or Caregiver
MENU